A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals
about
Vaccines against malariaNeutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic ReviewComparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IABPhase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectorsTransgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adultsA randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonistsPhase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins.Non-apical membrane antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay.Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccineComparing the understanding of subjects receiving a candidate malaria vaccine in the United States and MaliPhase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.Blood stage vaccines for Plasmodium falciparum: current status and the way forward.The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirusImmunogenicity of a peptide-based anti-IgE conjugate vaccine in non-human primates.TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models.Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets.Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.Recent progress concerning CpG DNA and its use as a vaccine adjuvant.Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine.CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-γ responsesFunctionally Distinct Subpopulations of CpG-Activated Memory B Cells.Production, characterisation and immunogenicity of a plant-made Plasmodium antigen--the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1.
P2860
Q17485685-B079BE2E-ED42-460E-9D52-D39D73DE20B9Q26700078-04535D4E-1BB6-4E81-81A0-FB9CC15E8F25Q27490878-DD824180-9075-4D6A-A882-7FAE4DBD723FQ28731894-54C0ECED-F052-4C47-8630-9D37433284C2Q28743564-DCF88D38-40BE-4A73-A35B-81E0773BAD2DQ28749215-1757A856-E44B-4272-BABC-48CF2ED780DDQ33598040-F8517E3D-271D-43DE-AD5E-736E547E6AE2Q33721641-2A3181CC-48D4-40F4-B3C8-FF4643D87338Q33762869-5210205A-19AB-4ECB-87E8-DF41E5DA1AFBQ33784812-33AAC238-4C96-485C-8D27-0ACF66514E9BQ33939405-C66C29E3-1F09-48C9-8402-5D968CAC5FA0Q33974904-EFC09DE7-BDEA-40E2-91AD-A9117E57B688Q34011922-BF272B60-9D42-4261-BC8C-4987011D8155Q34160143-F0805C85-AFE3-49F5-83F6-8577E28CA31CQ34441098-C68A7F51-BEE1-44FF-B4F1-0DF71029D27DQ34600955-F341D00B-4BC1-4E73-94B4-252F060B4845Q34613585-96BA8437-A3E4-43CB-89F3-8DDA0B90C2B1Q34663978-A0C775A1-143A-485A-9306-ACED615C2FDBQ35177864-C8EBF075-7FD5-4425-9C36-1512B2AF1AC9Q36933639-D098A48A-F70E-4ECD-8695-9C7063BBCEEEQ37384724-D03D2DF5-B1CC-4F66-B287-72745D3840AFQ38096489-9786385A-ABA4-4AB4-B06F-98CC96AC12ECQ38096490-102B8B3E-66D9-4C3A-ADEE-F58345C743E8Q38168903-51DED0AF-2A96-4C4D-9041-B75746F69FBFQ38775588-71DD987F-7389-4B45-99C2-B5055C6C8325Q39657741-E108F2CB-E854-404C-B1AD-DD46B588B991Q42030999-35046CCF-FA6C-4BCF-AA62-99D9B52A4D51Q46135249-D405FD9E-E065-46F5-AF81-968175AD1A87
P2860
A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A Phase 1 study of the blood-s ...... mulations and dosing intervals
@en
A Phase 1 study of the blood-s ...... ulations and dosing intervals.
@nl
type
label
A Phase 1 study of the blood-s ...... mulations and dosing intervals
@en
A Phase 1 study of the blood-s ...... ulations and dosing intervals.
@nl
prefLabel
A Phase 1 study of the blood-s ...... mulations and dosing intervals
@en
A Phase 1 study of the blood-s ...... ulations and dosing intervals.
@nl
P2093
P2860
P50
P1433
P1476
A Phase 1 study of the blood-s ...... mulations and dosing intervals
@en
P2093
Donna Shaffer
Gregory E D Mullen
Laura B Martin
Mark Pierce
P2860
P304
P356
10.1016/J.VACCINE.2009.04.077
P407
P577
2009-05-15T00:00:00Z